Literature DB >> 2951735

Selection and characterization of T-cell variants lacking molecules involved in T-cell activation (T3 T-cell receptor, T44, and T11): analysis of the functional relationship among different pathways of activation.

A Moretta, A Poggi, D Olive, C Bottino, C Fortis, G Pantaleo, L Moretta.   

Abstract

A clone of the interleukin 2-producing Jurkat leukemia cell line termed JA3 (surface phenotype, T3+, Ti+, T44+, T11+, T40+) has been used to induce and select cell variants lacking surface molecules involved in T-cell activation. Following 200 rad of gamma-radiation (1 rad = 0.01 Gy), cells were treated with monoclonal antibodies (mAbs) directed to T3, Ti, T44, or T11 antigen and complement. After growth of the residual cells in culture, "negative" cells were cloned under limiting conditions. Depending on the specificity of the mAb used for the immunoselection, three groups of variants were obtained. (i) The use of mAbs directed to T3 or Ti resulted in cell variants that expressed the T3 Ti- T44+ Leu1+ T11+ T40+ 4F2+ HLA class I+ surface phenotype. (ii) Immunoselection with anti-T44 mAb resulted in 2 variants that shared the T3- Ti- T44- Leu1- T11+ T40+ 4F2+ HLA class I+ phenotype. (iii) Cell treatment with anti-T11 mAb resulted in 15 variants characterized by the lack of T11 antigen expression and of all the other T-cell-specific surface antigens. Therefore, it appears that the different sets of JA3 cell variants, like T cells at discrete stages of intrathymic differentiation, may follow a coordinated expression of surface differentiation antigens. Analysis of the functional responsiveness of the three distinct groups of JA3 cell variants to different stimuli showed that all produced interleukin 2 in response to A23187 calcium ionophore plus phorbol 12-myristate 13-acetate. The first group of variants (T3- Ti-) did not respond to stimulation with anti-T3, anti-Ti, or anti-T44 mAbs. Eight of 9 did not respond to phytohemagglutinin either; however, all responded to appropriate stimulatory combinations of anti-T11 mAbs (and to calcium ionophore). The second group of variants (T3-, Ti-, T44-, T11+), similar to the first group, did not respond to anti-T3, anti-Ti, anti-T44 mAbs, and phytohemagglutinin, but they were fully responsive to anti-T11 mAb. The last group of variants (lacking all the T-cell-specific surface antigens) only responded to calcium ionophore A23187.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2951735      PMCID: PMC304495          DOI: 10.1073/pnas.84.6.1654

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Modulation of surface T11 molecules induced by monoclonal antibodies: analysis of the functional relationship between antigen-dependent and antigen-independent pathways of human T cell activation.

Authors:  A Moretta; D Olive; A Poggi; G Pantaleo; C Mawas; L Moretta
Journal:  Eur J Immunol       Date:  1986-11       Impact factor: 5.532

2.  Activation of human thymocytes via the 50KD T11 sheep erythrocyte binding protein induces the expression of interleukin 2 receptors on both T3+ and T3- populations.

Authors:  D A Fox; R E Hussey; K A Fitzgerald; A Bensussan; J F Daley; S F Schlossman; E L Reinherz
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Requirement for the coexpression of T3 and the T cell antigen receptor on a malignant human T cell line.

Authors:  A Weiss; J D Stobo
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

5.  An alternative pathway of T-cell activation: a functional role for the 50 kd T11 sheep erythrocyte receptor protein.

Authors:  S C Meuer; R E Hussey; M Fabbi; D Fox; O Acuto; K A Fitzgerald; J C Hodgdon; J P Protentis; S F Schlossman; E L Reinherz
Journal:  Cell       Date:  1984-04       Impact factor: 41.582

6.  Clonotypic surface structure on human T lymphocytes: functional and biochemical analysis of the antigen receptor complex.

Authors:  E L Reinherz; O Acuto; M Fabbi; A Bensussan; C Milanese; H D Royer; S C Meuer; S F Schlossman
Journal:  Immunol Rev       Date:  1984-10       Impact factor: 12.988

7.  Human cytotoxic T cell structures associated with expression of cytolysis. I. Analysis at the clonal cell level of the cytolysis-inhibiting effect of 7 monoclonal antibodies.

Authors:  B Malissen; N Rebai; A Liabeuf; C Mawas
Journal:  Eur J Immunol       Date:  1982-09       Impact factor: 5.532

8.  Frequency and surface phenotype of human T lymphocytes producing interleukin 2. Analysis by limiting dilution and cell cloning.

Authors:  A Moretta
Journal:  Eur J Immunol       Date:  1985-02       Impact factor: 5.532

9.  Phaseolus vulgaris phytohaemagglutinin (PHA) binds to the human T lymphocyte antigen receptor.

Authors:  O P Chilson; A W Boylston; M J Crumpton
Journal:  EMBO J       Date:  1984-12-20       Impact factor: 11.598

10.  Clonotypic structures involved in antigen-specific human T cell function. Relationship to the T3 molecular complex.

Authors:  S C Meuer; K A Fitzgerald; R E Hussey; J C Hodgdon; S F Schlossman; E L Reinherz
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

View more
  27 in total

1.  Defective signal transduction by the CD2 molecule in immature T-cell receptor/CD3- thymocytes.

Authors:  L A Turka; M C Fletcher; N Craighead; C B Thompson; C H June
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

2.  Human CD8+ T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations.

Authors:  M C Mingari; F Schiavetti; M Ponte; C Vitale; E Maggi; S Romagnani; J Demarest; G Pantaleo; A S Fauci; L Moretta
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

3.  Mutants of cultured mouse cells deficient in Ly-2 antigen.

Authors:  D Iannelli; R Palomba; R Capparelli; F Scala; A Iannelli; L Ferrara; T Uchida
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

4.  Mitogen-induced genes are subject to multiple pathways of regulation in the initial stages of T-cell activation.

Authors:  S G Irving; C H June; P F Zipfel; U Siebenlist; K Kelly
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

5.  Monoclonal antibodies specific for murine CD2 reveal its presence on B as well as T cells.

Authors:  H Yagita; T Nakamura; H Karasuyama; K Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

6.  Extrathymic differentiation of T lymphocytes and natural killer cells from human embryonic liver precursors.

Authors:  A Poggi; M Sargiacomo; R Biassoni; N Pella; S Sivori; V Revello; P Costa; M Valtieri; G Russo; M C Mingari
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

7.  Relative over-reactivity of human versus chimpanzee lymphocytes: implications for the human diseases associated with immune activation.

Authors:  Paula C Soto; Lance L Stein; Nancy Hurtado-Ziola; Stephen M Hedrick; Ajit Varki
Journal:  J Immunol       Date:  2010-03-15       Impact factor: 5.422

8.  Human T cells recovered from human/Balb radiation chimeras are hypersensitive to human immunodeficiency virus type 1 infection.

Authors:  O Shapira-Nahor; H Marcus; H Segall; I Lubin; S Slavin; A Panet; Y Reisner
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

9.  T-cell activation. V. Anti-major histocompatibility complex class I antibody-induced activation and clonal abortion in Jurkat T-leukaemic cells.

Authors:  M H Claesson; S Dissing; T Tscherning; C Geisler
Journal:  Immunology       Date:  1993-03       Impact factor: 7.397

Review 10.  The effect of aging on host defences. Implications for therapy.

Authors:  A Scordamaglia; G Ciprandi; F Indiveri; G W Canonica
Journal:  Drugs Aging       Date:  1991 Jul-Aug       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.